Q-omics provides the consensus-scored RAD23BP3 profile across patient tissues and cancer cell-line models. RAD23BP3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAD23BP3 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RAD23BP3 RNA expression shows 5,031 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, and BRCA as cancer lineages where RAD23BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD23BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD23BP3 survival associations across molecular data types. RAD23BP3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD23BP3 RNA expression–survival associations across cancer types. High RAD23BP3 expression shows unfavorable associations in ACC, READ, UCEC, LUSC, THCA and PCPG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAD23BP3 RNA expression.
This table summarizes RAD23BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAD23BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD23BP3 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA, KIRC and HNSC. The BRCA box plot shows higher RAD23BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .001).
This table shows molecular features associated with RAD23BP3 in patient tissues and cancer cell lines. In patient samples, RAD23BP3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
